Tags

Type your tag names separated by a space and hit enter

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
bioRxiv. 2020 May 22B

Abstract

During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

Authors+Show Affiliations

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Hospital Program Direction, The Rockefeller University, New York, NY 10065, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Hospital Clinical Research Office, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.Chan Zuckerberg Biohub, 499 Illinois Street, San Francisco, CA 94158, USA.Chan Zuckerberg Biohub, 499 Illinois Street, San Francisco, CA 94158, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA. Howard Hughes Medical Institute.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA. Howard Hughes Medical Institute.

Pub Type(s)

Preprint

Language

eng

PubMed ID

32511384

Citation

Robbiani, Davide F., et al. "Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals." BioRxiv : the Preprint Server for Biology, 2020.
Robbiani DF, Gaebler C, Muecksch F, et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv : the preprint server for biology. 2020.
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H. H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., ... Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2020.05.13.092619
Robbiani DF, et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv : the preprint server for biology. 2020 May 22; PubMed PMID: 32511384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. AU - Robbiani,Davide F, AU - Gaebler,Christian, AU - Muecksch,Frauke, AU - Lorenzi,Julio C C, AU - Wang,Zijun, AU - Cho,Alice, AU - Agudelo,Marianna, AU - Barnes,Christopher O, AU - Gazumyan,Anna, AU - Finkin,Shlomo, AU - Hagglof,Thomas, AU - Oliveira,Thiago Y, AU - Viant,Charlotte, AU - Hurley,Arlene, AU - Hoffmann,Hans-Heinrich, AU - Millard,Katrina G, AU - Kost,Rhonda G, AU - Cipolla,Melissa, AU - Gordon,Kristie, AU - Bianchini,Filippo, AU - Chen,Spencer T, AU - Ramos,Victor, AU - Patel,Roshni, AU - Dizon,Juan, AU - Shimeliovich,Irina, AU - Mendoza,Pilar, AU - Hartweger,Harald, AU - Nogueira,Lilian, AU - Pack,Maggi, AU - Horowitz,Jill, AU - Schmidt,Fabian, AU - Weisblum,Yiska, AU - Michailidis,Eleftherios, AU - Ashbrook,Alison W, AU - Waltari,Eric, AU - Pak,John E, AU - Huey-Tubman,Kathryn E, AU - Koranda,Nicholas, AU - Hoffman,Pauline R, AU - West,Anthony P,Jr AU - Rice,Charles M, AU - Hatziioannou,Theodora, AU - Bjorkman,Pamela J, AU - Bieniasz,Paul D, AU - Caskey,Marina, AU - Nussenzweig,Michel C, Y1 - 2020/05/22/ PY - 2020/6/9/entrez PY - 2020/6/9/pubmed PY - 2020/6/9/medline JF - bioRxiv : the preprint server for biology N2 - During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective. UR - https://www.unboundmedicine.com/medline/citation/32511384/Convergent_Antibody_Responses_to_SARS_CoV_2_Infection_in_Convalescent_Individuals_ L2 - https://doi.org/10.1101/2020.05.13.092619 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.